{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"}],"units":"Participants"}],"description":"Mean (STD) among patients achieving complete remission (CR)\n\nMyeloma Response Definitions - Using International Uniform Response Criteria:\n\nComplete Response (CR):\n\n* Absence of the original monoclonal paraprotein\n* \\<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy\n* No increase in size or number of lytic bone lesions\n* Disappearance of soft tissue plasmacytomas","dispersionType":"Standard Deviation","groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"paramType":"MEAN","populationDescription":"Data was not available on everyone for this endpoint so could only evaluable for 308 out of 363 patients due to data for participants is not available as the EPIC system was not in place when this study was conducted and participants moved to different clinics we do not have follow-up details.","reportingStatus":"POSTED","timeFrame":"12 months post transplant","title":"Time to Attainment of CR","type":"SECONDARY","unitOfMeasure":"months"}